Annual Reviews (publisher)

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Retrieved on: 
Wednesday, April 17, 2024
Professional Services, Health, Finance, Clinical Trials, General Health, Biotechnology, Corporation, Meta-analysis, Pregnancy, Risk, Woman, Poster, Annual Reviews (publisher), Research, Development, Knowledge, Data, Patient, AMCP, Annual general meeting, Dietary supplement

These rates are consistent with Rallybio’s current estimate of annual at-risk pregnancies and translate to tens of thousands of fetuses and newborns at risk each year for the potentially devastating consequences of FNAIT.

Key Points: 
  • These rates are consistent with Rallybio’s current estimate of annual at-risk pregnancies and translate to tens of thousands of fetuses and newborns at risk each year for the potentially devastating consequences of FNAIT.
  • Rallybio is on track to initiate a Phase 2 dose confirmation study for RLYB212 in pregnant women in the second half of 2024.
  • The poster, titled “Fetal and Neonatal Alloimmune Thrombocytopenia: A Systematic Literature Review and Meta-analysis of Adverse Pregnancy-Related Outcomes to Support the Development of a Novel Prophylactic Therapeutic,” was presented by Andrea V. Margulis of RTI Health Solutions.
  • The meta-analysis is based on 12 observational cohort studies from Europe, Canada, and Egypt published from 1985 through 2018.

Dr. Aysun Alagoz Exposes Corrupt U.S. Healthcare Practice in Fearless Memoir - Sham Peer Reviews Ignore Due Process, Threaten Patient Safety, and Destroy Physician Careers

Retrieved on: 
Monday, April 8, 2024
Malpractice, Name, Patient, SAN, National Practitioner Data Bank, Hospital, Peer, Alagöz, Peer review, Sham peer review, Annual Reviews (publisher), Health, Physician, Fear, Medical device

SAN ANTONIO, April 8, 2024 /PRNewswire/ -- During one routine Monday morning in the middle of May, 2011, OB/GYN Dr. Aysun Alagoz had no idea that her entire career and private practice were about to be upended. At odds with a powerful hospital administrator who branded Dr. Alagoz a "Disruptive Physician," she became the target for a common and often shady practice used by hospitals: the Peer Review. 

Key Points: 
  • At odds with a powerful hospital administrator who branded Dr. Alagoz a "Disruptive Physician," she became the target for a common and often shady practice used by hospitals: the Peer Review.
  • But used punitively, in a process called a Sham Peer Review, it can be leveraged to fire physicians, install handpicked cronies, leave patients stranded, and save hospitals money.
  • "The Sham Peer Review is an open, dirty secret in the U.S. healthcare system," said Dr. Alagoz.
  • The Sham Peer Reviews used by many hospital administrators and boards to remove any doctor they don't like, or disagree with, or as a way to save healthcare corporations money."

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Retrieved on: 
Monday, April 1, 2024
Professional Services, Health, Finance, Clinical Trials, General Health, Biotechnology, AMCP, Development, Risk, Patient, Corporation, CDT, Annual Reviews (publisher), Meta-analysis, Annual general meeting

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that data from a systematic literature review assessing the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk among pregnant mothers will be presented at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting in New Orleans from April 15th to 18th.

Key Points: 
  • Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that data from a systematic literature review assessing the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk among pregnant mothers will be presented at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting in New Orleans from April 15th to 18th.
  • Rallybio is developing RLYB212, a novel human monoclonal anti-HPA-1a antibody designed to prevent alloimmunization in at-risk pregnant mothers, thereby eliminating the risk of FNAIT and its potentially devastating consequences in fetuses and newborns.
  • Details of the poster presentation are as follows:
    Title: Fetal and Neonatal Alloimmune Thrombocytopenia: A Systematic Literature Review and Meta-analysis of Adverse Pregnancy-Related Outcomes to Support the Development of a Novel Prophylactic Therapeutic
    Poster Session Date and Time: April 17, 2024, 1:00 - 2:30 p.m. CDT (2:00 - 3:30 p.m. EDT)
    Additional information about the AMCP 2024 Annual Meeting is available at: https://amcpannual.org/

HCLTech placed in Customers’ Choice quadrant in 2023 Gartner® Peer Insights™ for Voice of the Customer: Data Center Outsourcing and Hybrid Infrastructure Managed Services

Retrieved on: 
Monday, February 12, 2024
Data Management, Technology, Software, Networks, Artificial Intelligence, Internet, Human voice, Magic Quadrant, G2000, Magic, AI, Research, Annual Reviews (publisher), MAGIC, Worldwide, DCO, Customer, Automation, Publication, Partnership

HCLTech , a leading global technology company, received the highest number of overall responses and was placed in Customers’ Choice quadrant in November 2023 Gartner® Peer Insights™ for Voice of the Customer: Data Center Outsourcing and Hybrid Infrastructure Managed Services, Worldwide .

Key Points: 
  • HCLTech , a leading global technology company, received the highest number of overall responses and was placed in Customers’ Choice quadrant in November 2023 Gartner® Peer Insights™ for Voice of the Customer: Data Center Outsourcing and Hybrid Infrastructure Managed Services, Worldwide .
  • HCLTech is also a Leader in the 2023 Gartner® Magic Quadrant™ for Data Center Outsourcing and Hybrid Infrastructure Managed Services Worldwide (DCO & HIMS), making it the only Global IT service provider to be recognized in both the 2023 Magic Quadrant report and the November 2023 Gartner® Peer Insights™ for Voice of the Customer: Data Center Outsourcing and Hybrid Infrastructure Managed Services, Worldwide.
  • Click here to learn more about the Peer Reviews for HCLTech Data Center Outsourcing and Hybrid Infrastructure Managed Services, Worldwide, November 2023.
  • Gartner, Voice of the Customer for Data Center Outsourcing and Hybrid Infrastructure Managed Services, Worldwide, 30 November 2023
    Gartner, Magic Quadrant for Data Center Outsourcing and Hybrid Infrastructure Managed Services, Worldwide, 27 June 2023, DD Mishra, et.

Mid-Atlantic Based Accounting & Business Consulting Firm Refreshes Online Identity & Launches New Website

Retrieved on: 
Thursday, December 21, 2023
Accounting, Multimedia, Chartered, Consultant, Annual Reviews (publisher), MBA, Associate, Knowledge, CVA, Pass, PFS, CBEC, CC

BALTIMORE, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Leonard J. Miller & Associates Chartered, a Maryland based certified public accounting firm, announced today a brand refresh. They unveiled a new website to reflect the organization's wide range of services and to showcase their core values.

Key Points: 
  • Leonard J. Miller & Associates Chartered, a Maryland based certified public accounting firm, announced today a brand refresh.
  • BALTIMORE, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Leonard J. Miller & Associates Chartered, a Maryland based certified public accounting firm, announced today a brand refresh.
  • "Our new online identity reflects our values, showcases our capabilities, and allows our clients to fully understand who we are as an organization.
  • The Leonard J. Miller & Associates firm specializes in sophisticated auditing, accounting, business consulting and tax services for a diverse client base.

Florida Cancer Specialists & Research Institute Contributing to Cutting-Edge Advancements in Hematology Science

Retrieved on: 
Wednesday, December 13, 2023
Annual Reviews (publisher), ASH, BTK, Research, Bortezomib, Omicron, Conference, Bangladesh Technical Education Board, Poster, Mantle cell lymphoma, SLL, Risk, Science, Abstract, Drug development, Tyrosine kinase, Society, B-cell lymphoma, FACP, Rituximab, Reversibility, Delta, Phase, Nivolumab, Hospital, Safety, DRD, MCL, FCS, FDA, Lymphocytosis, Pivotal trial, Chronic lymphocytic leukemia, Meta-analysis, Artery, Bias, Coronary thrombosis, NHL, CLL, Pharmaceutical industry, Dietary supplement, Vaccine, Birth control, Incidence, Patient, Dexamethasone, Lenalidomide, Hematology, Relapse, Dacarbazine, MD, Doxorubicin

FORT MYERS, Fla., Dec. 13, 2023 /PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition in San Diego on Dec. 9 - 12, 2023. Scientific abstracts submitted by FCS hematologists and medical oncologists were among the 7,000 accepted submissions selected through an extensive peer review process.

Key Points: 
  • FORT MYERS, Fla., Dec. 13, 2023 /PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition in San Diego on Dec. 9 - 12, 2023.
  • Scientific abstracts submitted by FCS hematologists and medical oncologists were among the 7,000 accepted submissions selected through an extensive peer review process.
  • Pirtobrutinib has also been approved for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
  • Once again, FCS is proud to have a strong presence, sharing the latest and most promising research and science that is moving the field forward."

Sorcero AI Platform™ Transforms Medical Affairs Teams for Improved Patient Outcomes in Fall '23 Release

Retrieved on: 
Wednesday, September 27, 2023
KOL, Medical Affairs Bureau, Reuters, Annual Reviews (publisher), Internet, Intelligence, Research, Key, HCP, Language, NLP, Organization, Philosophy, Publication, Patient, Data, MA, AI, FDA, Safety, Medical device, Risk management

WASHINGTON, Sept. 27, 2023 /PRNewswire-PRWeb/ -- Sorcero, the leading provider of advanced AI solutions purpose-built for Life Sciences organizations, today announced the expansion of the Sorcero AI Platform to include Sorcero iSLR™ for Systematic Literature Review and Sorcero PLS™ for Plain Language Summaries. The new solutions broaden the scope of Sorcero's omnichannel analytics platform as the firm continues to add new ways to help Medical Affairs teams (MA) uncover more insights from a multitude of sources in significantly less time.

Key Points: 
  • "With Sorcero's AI platform, Medical Affairs teams can capitalize on the abundance of biomedical data to accelerate the adoption of their life-saving therapies."
  • The Sorcero AI Platform includes four products, Sorcero IPM™, Sorcero MIM™, Sorcero PLS™, Sorcero iSLR™.
  • Sorcero MIM (Medical Insight Management) revolutionizes the way Medical Affairs teams work by unifying evidence across all internal and external data sources.
  • Sorcero CEO and Co-founder, Dipanwita Das will be participating in a webinar titled, AI: The Key to Revolutionizing Medical Affairs?

New Research Presents Evidence Positive Action Program Associated with Lower Adolescent Substance Abuse in Chicago Public Schools

Retrieved on: 
Friday, March 10, 2023
Research, Self-control, California State University, Long Beach, United States Department of Education, Randomized controlled trial, Education, Abuse, Risk, Drinking, Substance Use & Misuse, Overalls, Education sciences, Substance abuse, Multi-year rate plan, Student, PAI, Substance, Institute of Education Sciences, Mental health, Summer learning loss, Annual Reviews (publisher), Volume, TTI, SEL, Nursing, Management

TWIN FALLS, Idaho, March 10, 2023 /PRNewswire/ -- The Positive Action Program has significant effects on substance use in adolescents, resulting in fewer reported experiences with substance abuse, according to an article recently published in Substance Use & Misuse. The program is developed by Positive Action, Inc. ("PAI"), the leading education and technology company for evidence-based social and emotional learning (SEL) programs.

Key Points: 
  • The study examined data from a longitudinal matched-pairs cluster-randomized control trial conducted in Chicago Public Schools.
  • Students in Positive Action Program schools reported fewer experiences with drinking, getting drunk, and overall substance use compared to those in control schools.
  • Researchers noted significant indirect effects of the Positive Action Program on substance use via changes in self-control.
  • "This research strengthens the scientific evidence supporting the effectiveness of the Positive Action Program in helping students avoid substance abuse."

Darena Solutions Launches MeldRx™ Hub: A Directory of Over 2000 FHIR API Endpoints of MeldRx™ Customers

Retrieved on: 
Wednesday, January 4, 2023
Annual Reviews (publisher), Patient, 21st Century Cures Act, Health, Directory, Laika (EHR testing framework), Luke, Patient Provider, ONC, Failure, Ecosystem, API, Darenan, CAP, Certification, FHIR, Medical device, Payment, Providers

ST. LOUIS, Jan. 4, 2023 /PRNewswire-PRWeb/ -- Darena Solutions announces the launch of MeldRx™ Hub, a centralized directory of FHIR Application Programming Interfaces (APIs) for healthcare organizations that are part of the MeldRx™ ecosystem. The Cures Act requires EHRs to publish FHIR API endpoints in a machine-readable and easily accessible format for free. By sharing these API endpoints publicly, EHRs can facilitate the exchange of healthcare data through third-party apps. MeldRx™ Hub helps EHRs and healthcare organizations meet this requirement and take advantage of the FHIR-based apps.

Key Points: 
  • The Cures Act requires EHRs to publish FHIR API endpoints in a machine-readable and easily accessible format for free.
  • By sharing these API endpoints publicly, EHRs can facilitate the exchange of healthcare data through third-party apps.
  • With streamlined processes, MeldRx™ can help EHRs address the (g)(10) FHIR API, the FHIR API activation, and the FHIR API Directory listing for all providers to achieve Cures Act compliance within days.
  • Darena Solutions delivers an Ecosystem of FHIR® enabled interoperability, regulatory compliance, and analytics solutions to EHRs, Providers, and Payers.

CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI

Retrieved on: 
Tuesday, September 13, 2022
Center, Pregnancy, USOTC, Patient, Immunodeficiency, CDC, Influenza, Research, Annual Reviews (publisher), Disease, CSL Limited, CSL, ASX, Effectiveness, COVID-19, Role, Antibody, Season, History, Virus, H5N1, DNA, Ageing, Identical, Mortality, Comparison, Risk, Hospital, Haemophilia, TIME, CSL Behring, Summit, New Jersey, Degenerative disease, Epidemiology, BST, Vaccine, Public health, Demonstration, 4, Korea Disease Control and Prevention Agency, Influenza-like illness, ILI, Association, Influenza A virus, Control, Intention, Vaccination, MF59, Meta-analysis, Option, Vital, Belgrade Fair – Hall 1, Biotechnology, R, Neuraminidase, Online shopping, Woman

Data derived from a broad range of seasonal and pandemic influenza studies, including an oral presentation of influenza risk factors, will be shared.

Key Points: 
  • Data derived from a broad range of seasonal and pandemic influenza studies, including an oral presentation of influenza risk factors, will be shared.
  • "At CSL Seqirus, vaccine innovation is in our DNA, which is reflected in our strong presence at OPTIONS XI," said S. Raja Rajaram, M.D., Head of Global Medical Strategy, CSL Seqirus.
  • Cost-Effectiveness of Quadrivalent Adjuvanted Influenza Vaccine with MF59 Versus a Standard-Dose Quadrivalent Influenza Vaccines in Spain.
  • Today, CSL including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor provides lifesaving products to patients in more than 100 countries and employs 30,000 people.